高级检索
梁能秀, 蓝光华, 鲁鸿燕, 曾小良, 覃祺, 陆春燕, 梁富雄. HIV/AIDS患者2 174例接受抗病毒治疗后生存分析[J]. 中国公共卫生, 2021, 37(3): 488-492. DOI: 10.11847/zgggws1127678
引用本文: 梁能秀, 蓝光华, 鲁鸿燕, 曾小良, 覃祺, 陆春燕, 梁富雄. HIV/AIDS患者2 174例接受抗病毒治疗后生存分析[J]. 中国公共卫生, 2021, 37(3): 488-492. DOI: 10.11847/zgggws1127678
LIANG Neng-xiu, LAN Guang-hua, LU Hong-yan, . Survival of 2 174 HIV/AIDS patients receiving antiretroviral therapy in Guangxi Zhuang Autonomous Region, 2003 – 2017[J]. Chinese Journal of Public Health, 2021, 37(3): 488-492. DOI: 10.11847/zgggws1127678
Citation: LIANG Neng-xiu, LAN Guang-hua, LU Hong-yan, . Survival of 2 174 HIV/AIDS patients receiving antiretroviral therapy in Guangxi Zhuang Autonomous Region, 2003 – 2017[J]. Chinese Journal of Public Health, 2021, 37(3): 488-492. DOI: 10.11847/zgggws1127678

HIV/AIDS患者2 174例接受抗病毒治疗后生存分析

Survival of 2 174 HIV/AIDS patients receiving antiretroviral therapy in Guangxi Zhuang Autonomous Region, 2003 – 2017

  • 摘要:
      目的  了解抗病毒治疗艾滋病病毒感染者/艾滋病(HIV/AIDS)患者生存情况,探讨影响治疗患者死亡的危险因素。
      方法  采用回顾性队列研究方法,收集2003 年12月 — 2017年12月31日在广西壮族自治区疾病预防控制中心(广西CDC)关爱门诊首次接受艾滋病抗病毒治疗的2 174例患者信息,采用寿命表法计算研究对象的死亡概率、生存概率和生存率,Cox 比例风险模型分析其影响因素。
      结果  2 174例患者开始治疗时的平均年龄为(35.35 ± 12.38)岁,平均观察时间为(64.34 ± 47.63)个月,截止观察终点14年生存率为89.79 %,总病死率为0.978/100人年,平均生存时间为158.27(95 % CI = 156.46~160.08)个月;Cox 多因素分析结果显示,入组治疗年龄、感染途径、基线CD4+T淋巴细胞计数(CD4)是生存时间的影响因素。
      结论  广西CDC关爱门诊抗病毒治疗患者累积生存概率较高,开始治疗年龄 < 30岁,CD4细胞计数 < 200个/μL,感染途径为同性性行为的患者死亡风险较高,建议加强对这类病人的临床诊疗和医学随访。

     

    Abstract:
      Objective  To analyze survival rate and its related factors in human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients with antiretroviral therapy (ART) in Guangxi Zhuang Autonomous Region (Guangxi).
      Methods  We collected information on 2 174 HIV/AIDS patients registered at health care clinics in Guangxi for their first ART from December 2003 through 2017 for a retrospective cohort study. The cumulative survival rate of patients was calculated with life table method and Cox proportional hazards model was used to analyze influencing factors of the patients′ survival.
      Results  The median age of the patients was 35.35 ± 12.38 years and the median duration of follow-up was 64.34 ± 47.63 months. The overall mortality was 0.978/100 person-years and the average survival time was 158.27 months (95% confidence interval = 156.46 – 160.08) with a 14-year survival rate of 89.79% by the end of the follow-up. The results of multivariate Cox regression analyses demonstated that age, baseline CD4+T lymphocyte cell count and transmission route were influential factors of the survival rate.
      Conclusion  The survival rate of patients receiving ART at health care clinics of Guangxi is relatively high, but special attention should be paid to the patients less than 30 years old and with a baseline CD4+T lymphocyte cell count less than 200/μL at the initial treatment, and those infected via homosexual transmission.

     

/

返回文章
返回